ArticleNanoscale advances2026
Investigation of cyclic peptides as drug delivery systems for the delivery of the anti-tuberculosis drug pyrazinamide.
Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the important goals of drug delivery in the treatment of diseases is to effectively deliver drugs to deep and inaccessible areas of tissues. In recent years, cyclic peptides (CPs) have been used as drug delivery systems due to their high affinity for their targets, stability against degradation, and low toxicity. In this study, the interaction of the anti-tuberculosis drug pyrazinamide (PY) with cyclic decapeptides of glycine, alanine, and serine and their binary alternating sequences was investigated at the M06-2X/6-31G(d,p) level of theory in the gas phase. Interaction energies, structural parameters, topological properties, and RDG, ELF, and IGM analyses were used to assess the strength of interactions in the complexes. The electronic properties of cyclic peptides were investigated and compared before and after the complexation process. Based on the findings of this study, cyclic peptides based on binary alternating sequences have a higher tendency to interact with the pyrazinamide molecule. Therefore, the use of a combination of amino acids in cyclic peptides allowed for the rational design of a new material with more favorable properties. These findings provide insights into the development of more effective drugs using cyclic peptides.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.